Pioneering biopharmaceutical company focused on developing innovative immunotherapies aimed at treating various immune-related diseases
Raised to date
$2.7M
of $4.5M offered across 2 Form D filings
With a commitment to advancing patient care through scientific research and development, Maxymune strives to harness the power of the immune system to improve health outcomes.
Maxymune stands out for its proprietary approaches that enhance immune system responses, setting the stage for transformational therapies in the field of immunotherapy.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Jun 3, 2026 | Option to acquire | $2.7M/ $4.5M | Form D/A |
| Feb 28, 2025 | Option to acquire | $850K/ $2.5M | Form D |
Immunotherapy
Maxymune-01 is an advanced immunotherapy product designed to target specific pathways in the immune system, enhancing the body's natural ability to fight off diseases. This flagship offering is undergoing pivotal clinical trials to evaluate its safety and efficacy.
Built for
Healthcare providers and immunocompromised patients
